



Voretigene Neparvovec for Biallelic RPE65-Mediated Retinal Disease: Effectiveness, Value, and Value-Based Price Benchmarks

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for its upcoming report on voretigene neparvovec for biallelic RPE65-mediated retinal disease. ICER will invite input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER often receives comments from individual patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- American Foundation for the Blind
- American Academy of Ophthalmology
- American Association for Pediatric Ophthalmology and Strabismus
- Foundation Fighting Blindness
- Massachusetts Association for the Blind and Visually Impaired
- National Federation for the Blind
- Retina International
- A Shared Vision
- Sofia Sees Hope
- Spark Therapeutics